Last Updated: August 3, 2026

Litigation Details for Noven Pharmaceuticals Inc. v. Actavis Laboratories UT Inc. (D. Del. 2015)

✉ Email this page to a colleague

« Back to Dashboard

Noven Pharmaceuticals Inc. v. Actavis Laboratories UT Inc. (D. Del. 2015)

Docket	1:15-cv-00249	Date Filed	2015-03-20
Court	District Court, D. Delaware	Date Terminated	2019-10-07
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	NOVEN PHARMACEUTICALS INC.
Patents	8,231,906
Attorneys	Christopher J. Morten
Firms	Polsinelli PC
Link to Docket	External link to docket

Small Molecule Drugs cited in Noven Pharmaceuticals Inc. v. Actavis Laboratories UT Inc.

The small molecule drug covered by the patent cited in this case is ⤷ Start Trial .

Details for Noven Pharmaceuticals Inc. v. Actavis Laboratories UT Inc. (D. Del. 2015)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2015-03-20				External link to document
2015-03-20	134		Michniak-Kohn, Ph.D. Concerning Invalidity of U.S. Patent No. 8,231,906 filed by Actavis Laboratories UT Inc..(Mowery…2015 7 October 2019 1:15-cv-00249 830 Patent None District Court, D. Delaware	External link to document
2015-03-20	138		Ph.D. Concerning Noninfringement of U.S. Patent No. 8,231,906 filed by Actavis Laboratories UT Inc..(Fineman…2015 7 October 2019 1:15-cv-00249 830 Patent None District Court, D. Delaware	External link to document
2015-03-20	142		Michniak-Kohn, Ph.D. Concerning Invalidity of U.S. Patent No. 8,231,906; (2) Expert Report of Walter H.A. Vandaele…2015 7 October 2019 1:15-cv-00249 830 Patent None District Court, D. Delaware	External link to document
2015-03-20	148		35 U.S.C. § 282 Regarding United States Patent No. 8,231,906 filed by Actavis Laboratories UT Inc..(Fineman…2015 7 October 2019 1:15-cv-00249 830 Patent None District Court, D. Delaware	External link to document
2015-03-20	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,231,906 B2;. (els) (Entered…2015 7 October 2019 1:15-cv-00249 830 Patent None District Court, D. Delaware	External link to document
2015-03-20	98		alleging infringement of U.S. Patent No. 8,231,906 (the '"906 patent"), which is directed …quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent specification …ultimate question of the proper construction of a patent is a question oflaw. See Teva Pharm. USA, Inc.…light of the statutes and policies that inform patent law." Id. "[T]he words of a claim	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.